01 June 2005 : Original article
Use of recombinant human activated protein C in treatment of severe sepsis in a pregnant patient with fully symptomatic ovarian hyperstimulation syndrome
Małgorzata Mikaszewska-Sokolewicz, Ewa Mayzner-ZawadzkaMed Sci Monit 2005; 11(6): CS27-32 :: ID: 16511
Abstract
Summary
Background: Severe sepsis during pregnancy is a life-threatening condition for the mother, due to multiorgan failure and uncontrolled infl ammatory response. It is associated with high risk of death for the fetus.
Case Report: The paper presents the course and treatment of severe iatrogenic sepsis in a patient in very early pregnancy. The sepsis was a result of complications after overstimulation of the ovaries in the
course of treatment of infertility. The risk of the patient’s death, assessed in the Intensive Care Unit according to APACHE II and SAPS II scores was 73%, whereas indirect assessment of the embryo
in the 3[sup]rd[/sup] week of pregnancy, based on determination of serum gestational hormone levels was ambiguous, but rather unfavorable. The patient’s condition improved considerably after intensive treatment, including, among others, the use of activated protein C (APC). After the completion of treatment, in the 5[sup]th[/sup] week of pregnancy, the gestational hormone levels increased to the values appropriate for such fetal age. The development of pregnancy was also confi rmed by ultrasonography.
Conclusions: The paper presents a case of severe sepsis in the course of ovarian hyperstimulation syndrome, not described in the literature so far, as well as the fi rst successful administration of activated protein C in 21-day pregnancy.
Keywords: Ovarian Hyperstimulation Syndrome - drug therapy, Ovarian Hyperstimulation Syndrome - physiopathology, Pregnancy Complications, Infectious - drug therapy, Pregnancy Complications, Infectious - physiopathology, APACHE, Cardiac Output, Heart Rate, Ovarian Hyperstimulation Syndrome - physiopathology, Platelet Count, Pregnancy, Pregnancy Complications, Infectious - physiopathology, Protein C - therapeutic use, Recombinant Proteins - therapeutic use, Sepsis - etiology, Stroke Volume
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952